Equities
Health CarePharmaceuticals and Biotechnology
  • Price (EUR)225.00
  • Today's Change-2.00 / -0.88%
  • Shares traded26.77k
  • 1 Year change+50.40%
  • Beta0.9731
Data delayed at least 15 minutes, as of Feb 06 2026 16:37 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Financiere de Tubize SA is a Belgium-based holding company. The Company holds minor capital in UCB SA. UCB is a Belgian pharmaceutical and specialty chemical company that specializes in two therapeutic areas: diseases of the central nervous system (CNS) and immunology. UCB, together with its subsidiaries, has research and development facilities in Belgium, Germany, Japan, the United Kingdom and the United States. The Company promotes the development of a sustainable biopharma ecosystem in Belgium and possibly in other geographic areas relevant to UCB.

  • Revenue in EUR (TTM)0.00
  • Net income in EUR92.74m
  • Incorporated1928
  • Employees--
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Zydus Lifesciences Ltd2.30bn462.55m8.56bn27.92k18.513.6015.233.7248.9048.89243.42251.510.62531.605.098,773,830.0012.7010.9217.0216.3572.4063.1220.3016.731.44--0.255417.8118.9010.2717.9630.9213.6325.74
Biomarin Pharmaceutical Inc2.63bn441.89m9.32bn3.04k21.421.8118.203.552.672.6715.8231.530.42780.45123.951,017,764.007.202.188.042.4681.3276.4316.826.073.10--0.08970.0017.9710.86154.62---9.83--
Lupin Ltd2.33bn406.57m9.53bn19.98k23.495.1618.014.1094.4394.43540.38429.820.83931.254.3412,388,350.0014.744.5321.747.1671.7059.7017.575.951.32110.560.239629.1313.488.1171.41--20.1114.87
Avidity Biosciences Inc17.72m-466.83m9.57bn391.00--5.67--539.97-4.17-4.170.158912.850.0111--2.7853,370.84-29.13-30.46-31.29-33.14-----2,634.59-1,901.74----0.00--13.9936.27-51.87--97.52--
Dr Reddy's Laboratories Ltd3.26bn523.50m9.74bn26.94k18.63--13.862.9966.8166.81416.15--------12,871,960.00--12.15--16.9465.7666.1815.9215.81--19.79--14.6916.5413.261.3822.8441.269.86
Recordati Industria Chmc Frmctc SpA2.55bn404.39m10.04bn4.58k24.455.0916.383.931.961.9612.409.420.53771.814.87557,416.808.5110.5010.7113.4667.6669.8915.8319.981.168.300.565136.9812.459.587.012.4613.944.90
Financiere de Tubize SA0.0092.74m10.10bn--108.955.22108.95--2.082.080.0043.490.00------4.815.684.855.89------230.34----0.0030.18----2.22-20.50--10.90
Cipla Ltd2.67bn427.42m10.13bn30.31k23.70--19.343.8056.2656.26350.81--------9,352,779.00--11.89--14.4966.5359.5516.0314.74--96.40--22.406.889.9727.9327.809.1434.08
Orion Oyj1.63bn313.30m10.22bn4.03k32.5410.0228.166.282.232.2311.597.240.97071.556.55419,768.0018.6620.1426.0824.6759.6659.7219.2221.161.19101.620.23484.2529.657.9752.1710.4819.141.80
Elanco Animal Health Inc3.90bn30.57m10.26bn9.00k339.431.7917.112.630.07160.07169.2313.580.34221.245.30510,111.100.2683-2.710.2993-3.0254.9654.720.7841-9.521.231.300.3735--0.49817.65127.4637.85-3.99--
BridgeBio Pharma Inc300.40m-676.84m10.43bn725.00------34.71-4.19-4.191.86-10.030.4254----487,972.40-96.88-75.74-125.35-94.2495.7896.67-227.74-716.923.76-2.893.52--2,285.2740.4816.70--11.63--
Ipsen SA3.76bn447.90m11.37bn5.36k25.272.6513.243.025.375.3745.0751.130.56212.385.13701,717.106.7410.348.7613.9683.3282.8911.9917.791.80130.370.170416.958.115.83-42.33--22.776.96
Neurocrine Biosciences Inc2.28bn363.42m11.68bn1.80k32.934.5830.055.134.194.1926.2530.130.68780.76114.441,490,389.0010.9710.4112.7112.7198.3798.4715.9515.713.27--0.00--24.8124.4836.6855.9420.97--
Data as of Feb 06 2026. Currency figures normalised to Financiere de Tubize SA's reporting currency: Euro EUR

Institutional shareholders

5.60%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 07 Jan 2026748.70k1.68%
Norges Bank Investment Managementas of 30 Jun 2025355.46k0.80%
BlackRock Fund Advisorsas of 09 Jan 2026325.98k0.73%
Fidelity Management & Research Co. LLCas of 30 Nov 2025257.11k0.58%
Geode Capital Management LLCas of 29 Jan 2026210.06k0.47%
BlackRock Advisors (UK) Ltd.as of 09 Jan 2026198.81k0.45%
Amundi Asset Management SASU (Investment Management)as of 27 Jan 2026143.15k0.32%
BNP Paribas Asset Management Europe SASas of 06 Jan 2026107.74k0.24%
JPMorgan Asset Management (UK) Ltd.as of 31 Dec 202582.94k0.19%
Degroof Petercam Asset Management SAas of 30 Sep 202564.00k0.14%
More ▼
Data from 30 Jun 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.